Study of Tirzepatide in Healthy Participants

NCT04311424 · Completed

Last updated 2026-05-28

This clinical trial tests how tirzepatide, a medication, is processed and eliminated from the body in healthy participants by measuring its radioactive levels in urine over time.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design open-label (no blinding) basic-science study

Participants 6 people

Who can join Ages 30–55 · male only Healthy volunteers accepted.

Timeline Started 2020-07 · est. completion 2020-10

Where 1 site · United Kingdom

What this study is testing ClinicalTrials.gov NCT04311424 ↗

Description as written by the study sponsor.

The purpose of this study is to look at how much tirzepatide gets into the bloodstream and how long the body takes to get rid of it. This study will involve a single dose of 14C radiolabelled tirzepatide. This means that a radioactive tracer substance, C14, will be incorporated into the study drug to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine, feces and expired air. Screening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be approximately 15 weeks, including screening.

Treatments tested

14C Tirzepatide also known as LY3298176 Drug

Administered SC.

Main thing measured	Urinary Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered
Sponsor	Eli Lilly and Company
Conditions studied	Healthy
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04311424 ↗